281 related articles for article (PubMed ID: 28710706)
1. Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures.
Cracolici V; Mujacic I; Kadri S; Alikhan M; Niu N; Segal JP; Rosen LE; Sarne DH; Morgan A; Desouky S; Cipriani NA
Endocr Pathol; 2018 Mar; 29(1):9-14. PubMed ID: 28710706
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
3. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.
Begum S; Rosenbaum E; Henrique R; Cohen Y; Sidransky D; Westra WH
Mod Pathol; 2004 Nov; 17(11):1359-63. PubMed ID: 15195111
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
6. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
[TBL] [Abstract][Full Text] [Related]
7. A mutation panel comprising BRAF
Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
[TBL] [Abstract][Full Text] [Related]
8. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
9. BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features.
Proietti A; Giannini R; Ugolini C; Miccoli M; Fontanini G; Di Coscio G; Romani R; Berti P; Miccoli P; Basolo F
Thyroid; 2010 Nov; 20(11):1263-70. PubMed ID: 20950194
[TBL] [Abstract][Full Text] [Related]
10. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor lesion?
Cameselle-Teijeiro J; Abdulkader I; Pérez-Becerra R; Vázquez-Boquete A; Alberte-Lista L; Ruiz-Ponte C; Forteza J; Sobrinho-Simões M
Hum Pathol; 2009 Jul; 40(7):1029-35. PubMed ID: 19269016
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
Kebebew E; Weng J; Bauer J; Ranvier G; Clark OH; Duh QY; Shibru D; Bastian B; Griffin A
Ann Surg; 2007 Sep; 246(3):466-70; discussion 470-1. PubMed ID: 17717450
[TBL] [Abstract][Full Text] [Related]
14. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
Griffith C; Zhang S; Mukhopadhyay S
Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
Jakubowski M; Hunt JL
Am J Surg Pathol; 2009 Nov; 33(11):1590-3. PubMed ID: 19738460
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
18. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
Zhu XL; Zhou XY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
[TBL] [Abstract][Full Text] [Related]
19. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
Trovisco V; Soares P; Preto A; de Castro IV; Lima J; Castro P; Máximo V; Botelho T; Moreira S; Meireles AM; Magalhães J; Abrosimov A; Cameselle-Teijeiro J; Sobrinho-Simões M
Virchows Arch; 2005 Jun; 446(6):589-95. PubMed ID: 15902486
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
